MedTrace Logo

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

NCT06124560 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-11-09

No results posted yet for this study

Summary

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fasting conditions.

Conditions

  • Bioequivalence
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet

The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet

Sponsors & Collaborators

  • Galenicum Health

    lead INDUSTRY

Principal Investigators

  • María Elena Cedano Limón · Avant Santé Research Center S.A. de C.V.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-28
Primary Completion
2022-11-07
Completion
2022-11-07

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06124560 on ClinicalTrials.gov